709 related articles for article (PubMed ID: 24833295)
1. Liver X receptors in lipid metabolism: opportunities for drug discovery.
Hong C; Tontonoz P
Nat Rev Drug Discov; 2014 Jun; 13(6):433-44. PubMed ID: 24833295
[TBL] [Abstract][Full Text] [Related]
2. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design.
Oosterveer MH; Grefhorst A; Groen AK; Kuipers F
Prog Lipid Res; 2010 Oct; 49(4):343-52. PubMed ID: 20363253
[TBL] [Abstract][Full Text] [Related]
3. Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism.
Xiao L; Xie X; Zhai Y
Adv Drug Deliv Rev; 2010 Oct; 62(13):1316-21. PubMed ID: 20659512
[TBL] [Abstract][Full Text] [Related]
4. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.
Wójcicka G; Jamroz-Wiśniewska A; Horoszewicz K; Bełtowski J
Postepy Hig Med Dosw (Online); 2007 Dec; 61():736-59. PubMed ID: 18063918
[TBL] [Abstract][Full Text] [Related]
5. Liver X receptor in cholesterol metabolism.
Zhao C; Dahlman-Wright K
J Endocrinol; 2010 Mar; 204(3):233-40. PubMed ID: 19837721
[TBL] [Abstract][Full Text] [Related]
6. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
Fiévet C; Staels B
Biochem Pharmacol; 2009 Apr; 77(8):1316-27. PubMed ID: 19101522
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptors: emerging therapeutic targets for Alzheimer's disease.
Sodhi RK; Singh N
Pharmacol Res; 2013 Jun; 72():45-51. PubMed ID: 23542729
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptors, atherosclerosis and inflammation.
Michael DR; Ashlin TG; Buckley ML; Ramji DP
Curr Atheroscler Rep; 2012 Jun; 14(3):284-93. PubMed ID: 22419222
[TBL] [Abstract][Full Text] [Related]
9. Selective liver X receptor modulators (SLiMs): what use in human health?
Viennois E; Mouzat K; Dufour J; Morel L; Lobaccaro JM; Baron S
Mol Cell Endocrinol; 2012 Apr; 351(2):129-41. PubMed ID: 21907760
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional and posttranscriptional control of cholesterol homeostasis by liver X receptors.
Tontonoz P
Cold Spring Harb Symp Quant Biol; 2011; 76():129-37. PubMed ID: 21859674
[TBL] [Abstract][Full Text] [Related]
11. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.
Quinet EM; Basso MD; Halpern AR; Yates DW; Steffan RJ; Clerin V; Resmini C; Keith JC; Berrodin TJ; Feingold I; Zhong W; Hartman HB; Evans MJ; Gardell SJ; DiBlasio-Smith E; Mounts WM; LaVallie ER; Wrobel J; Nambi P; Vlasuk GP
J Lipid Res; 2009 Dec; 50(12):2358-70. PubMed ID: 19318684
[TBL] [Abstract][Full Text] [Related]
12. Targeting liver X receptors in human health: deadlock or promising trail?
Viennois E; Pommier AJ; Mouzat K; Oumeddour A; El Hajjaji FZ; Dufour J; Caira F; Volle DH; Baron S; Lobaccaro JM
Expert Opin Ther Targets; 2011 Feb; 15(2):219-32. PubMed ID: 21204733
[TBL] [Abstract][Full Text] [Related]
13. Soy protein isoflavones differentially regulate liver X receptor isoforms to modulate lipid metabolism and cholesterol transport in the liver and intestine in mice.
González-Granillo M; Steffensen KR; Granados O; Torres N; Korach-André M; Ortíz V; Aguilar-Salinas C; Jakobsson T; Díaz-Villaseñor A; Loza-Valdes A; Hernandez-Pando R; Gustafsson JÅ; Tovar AR
Diabetologia; 2012 Sep; 55(9):2469-78. PubMed ID: 22739758
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Synthesis of a Novel Series of Liver X Receptor Antagonists.
Nian S; Gan X; Tan X; Yu Z; Wang P; Chen X; Wang G
Chem Pharm Bull (Tokyo); 2015; 63(8):628-35. PubMed ID: 26062802
[TBL] [Abstract][Full Text] [Related]
15. Liver x receptors: a potential therapeutic target for modulating the atherosclerotic process.
Parikh N; Frishman WH
Cardiol Rev; 2010; 18(6):269-74. PubMed ID: 20926935
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β Receptors: The Good, the Bad, and the Prion Protein.
Jarosz-Griffiths HH; Noble E; Rushworth JV; Hooper NM
J Biol Chem; 2016 Feb; 291(7):3174-83. PubMed ID: 26719327
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptors in immune cell function in humans.
Waddington KE; Jury EC; Pineda-Torra I
Biochem Soc Trans; 2015 Aug; 43(4):752-7. PubMed ID: 26551724
[TBL] [Abstract][Full Text] [Related]
18. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol.
Pfeifer T; Buchebner M; Chandak PG; Patankar J; Kratzer A; Obrowsky S; Rechberger GN; Kadam RS; Kompella UB; Kostner GM; Kratky D; Levak-Frank S
Curr Pharm Biotechnol; 2011 Feb; 12(2):285-92. PubMed ID: 21190543
[TBL] [Abstract][Full Text] [Related]
19. Machine learning identifies candidates for drug repurposing in Alzheimer's disease.
Rodriguez S; Hug C; Todorov P; Moret N; Boswell SA; Evans K; Zhou G; Johnson NT; Hyman BT; Sorger PK; Albers MW; Sokolov A
Nat Commun; 2021 Feb; 12(1):1033. PubMed ID: 33589615
[TBL] [Abstract][Full Text] [Related]
20. Liver X receptor modulators: a review of recently patented compounds (2009 - 2012).
Loren J; Huang Z; Laffitte BA; Molteni V
Expert Opin Ther Pat; 2013 Oct; 23(10):1317-35. PubMed ID: 23826715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
